Elite Pharmaceuticals Inc (OTCBB:ELTP) Soars In Opioid Market


Dallas, Texas 01/10/2014 (FINANCIALSTRENDS) – Elite Pharmaceuticals Inc (OTCBB:ELTP) the US-based pharmaceuticals is not a traditional drug manufacturer as some of the other big names in the industry such as Pfizer or Merck. Elite Pharmaceuticals is essentially involved in products which are off-patent. Secondly, Elite deals essentially with oral, sustained as well as controlled release products.  The pharma company trades at $0.14 per share on the OTC and has jumped 2.47% in the recent trading session. Elite Pharmaceuticals is a 73.65 million market cap company and has 2,078,926 volume.

Elite Pharmaceuticals Inc (OTCBB:ELTP) investor sentiment would move from the low-bound stock market to high net value pharma company given the good stockpile it has for 2014. With substantial number of products lined for FDA approval, the stock has recorded high of over 24% in January this year, as clinical trials on two of proposed drugs reached Phase III clinical test. Thus far, results appear to be efficient.

Of the many Elite Pharmaceuticals Inc (OTCBB:ELTP) drugs, the Oxycodone (ELI-201) is the biggest name-guzzler and poised to become a $2.7 billion market worth drug. It will enter, the already mature $8 billion opioid market. This will be for the twice-daily market share. The once-daily Oxycodone will also see trails by mid-March, and is expected to see quick market capture, considering the fact that there are no once daily drugs in the opioid market currently available.

Continuing in the opioid market segment, the company has already introduce four different products which will help in overcoming abuse of opioids.

Elite Pharma is also expected to see much action on nearly 8 new generic products that the company will now move into distribution stage.

Elite Pharmaceuticals Inc (OTCBB:ELTP) is working with Camargo, to ensure its drug-line up receives approval in-line with regulations -505(B)(2), and ensuring data- which FDA specifically requires is readily available when these drugs are under consideration by US highest-regulatory body.